GlobeNewswire PharmaOriginal article
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Data ReadoutpositivePRPPositive
AI Analysis
Summary
Propanc Biopharma announced positive preclinical and early translational data for PRP demonstrating >90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models. The mechanism targets cancer stem cells and disrupts the fibrotic microenvironment.
Outcome Details
>90% tumor growth inhibition and significant survival benefit in pancreatic ductal adenocarcinoma models
Importance:5/10
Sentiment:
0.75
preclinical dataearly translational datatumor growth inhibitioncancer stem cellspancreatic cancerfibrotic microenvironment
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 6, 2026 12:30 PM